We are committed to clinical studies that improve care for and recognize the needs of all patients. During 2023, the Open&Out (O&O) Employee Resource Group (ERG) drove a program to create new resources to improve our understanding of LGBTQIA+ health needs to mitigate their health risks. Approximately 20 dedicated doctors, scientists, clinical operations associates and activists were engaged to support J&J business teams in championing the unique healthcare needs of the LGBTQIA+ community.
This work contributed to a pioneering approach to clinical trial inclusion. Our LIBERTAS9 oncology clinical study, initiated in 2023, represents one of the first de-gendered and transgender-inclusive protocols in oncology as we aim to advance health equity for sexual and gender minorities. Through the LIBERTAS study, we hope to pioneer innovative clinical research that removes barriers and ensures inclusive representation in clinical studies.
9LIBERTAS is a study of an Intermittent Androgen-Deprivation Therapy (ADT) Approach with Apalutamide Monotherapy in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC).
